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Abstract
Background: BBK32 is a surface expressed lipoprotein and fibronectin (Fn)-binding microbial surface component
recognizing adhesive matrix molecule (MSCRAMM) of Borrelia burgdorferi, the causative agent of Lyme disease. Previous
studies from our group showed that BBK32 is a virulence factor in experimental Lyme disease and located the Fn-binding
region to residues 21–205 of the lipoprotein.
Methodology/Principal Findings: Studies aimed at identifying interacting sites between BBK32 and Fn revealed an
interaction between the MSCRAMM and the Fn F3 modules. Further analysis of this interaction showed that BBK32 can
cause the aggregation of human plasma Fn in a similar concentration-dependent manner to that of anastellin, the
superfibronectin (sFn) inducing agent. The resulting Fn aggregates are conformationally distinct from plasma Fn as
indicated by a change in available thermolysin cleavage sites. Recombinant BBK32 and anastellin affect the structure of Fn
matrices formed by cultured fibroblasts and inhibit endothelial cell proliferation similarly. Within BBK32, we have located the
sFn-forming activity to a region between residues 160 and 175 which contains two sequence motifs that are also found in
anastellin. Synthetic peptides mimicking these motifs induce Fn aggregation, whereas a peptide with a scrambled sequence
motif was inactive, suggesting that these motifs represent the sFn-inducing sequence.
Conclusions/Significance: We conclude that BBK32 induces the formation of Fn aggregates that are indistinguishable from
those formed by anastellin. The results of this study provide evidence for how bacteria can target host proteins to
manipulate host cell activities.
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Introduction
Different microbial pathogens use diverse sets of virulence
factors to establish infections. In fact, the panels of virulence
factors employed are often organism and host species specific and
sometimes also disease specific. Despite this variation, bacterial
infectious disease processes appear to involve some common steps.
The microbial pathogen usually has to adhere to a tissue(s) in the
host in order to establish a colony, and to survive, the microbe has
to evade the host’s defense systems.
In this context of diversity it is remarkable that so many
pathogenic organisms appear to bind and adhere to fibronectin
(Fn) substrates. Fn is an abundant animal glycoprotein found in a
soluble form in most body fluids and deposited as part of the
insoluble extracellular matrix of most tissues. The protein is
composed of two 220 KDa polypeptides held together by disulfide
bonds at the C-terminal end. Each polypeptide is a mosaic protein
composed of three types of repeating modules: 12 type I modules
(F1), 2 type II modules (F2), 15–17 (dependent on alternative
splicing) type III modules (F3), and an alternatively spliced
variable sequence that is not homologous to other parts of Fn. F1
and F2 modules are stabilized by disulfide bonds, whereas F3
modules lack disulfide bonds and can reversibly partially unfold
[1,2].
Soluble Fn adopts a somewhat compact form that is stabilized
by intramolecular ionic interactions between specific modules.
These interactions occur primarily between the
1F1–
5F1, the
2F3–
3F3, and
12F3–
14F3 segments [3]. In the extracellular matrix,
Fn takes on a more extended form and the protein is likely
engaged in multiple intra- and intermolecular interactions (for
review see [4]). The structural organizations of Fn matrices have
not been elucidated in detail; however, it is likely that the
incorporation of soluble Fn into a matrix involves a complex but
orderly breaking of intramolecular bonds in the compact soluble
Fn and the formation of new intra- and intermolecular
interactions. This process is facilitated by integrins and other
cellular components [5,6]. Recently Vakonakis, et al., suggested
that cell-generated tension on Fn, disrupts interactions between
1F3 and
2F3, creating a conformation of
1–2F3 that binds to the N-
terminal domain and initiates fibrillogenesis [7].
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proliferation, migration, differentiation, and survival by interacting
with a variety of extracellular macromolecules and cellular
receptors, primarily of the integrin family [8]. Integrins constitute
a family of dimeric cell surface receptors that recognize specific
extracellular matrix and cell bound ligands. Integrins a5b1, a4b1,
and avb3 are the primary Fn receptors.
Fn may occur in different aggregated forms. ‘‘Superfibronectin’’
(sFn) is a form of Fn aggregates that resembles Fn matrices, but
with distinct biological activities [9]. sFn is formed by mixing
plasma Fn with anastellin, a recombinant form of the C-terminal
two-thirds of the
1F3 Fn module. F3 modules are b-sandwiches
composed of a four-stranded b-sheet and a triple-stranded b-sheet.
In anastellin, strands A and B are removed, exposing the E and C
strands, which is perhaps responsible for anastellin’s self-
association and interaction with other Fn modules [10]. These
interactions lead to the formation of sFn. Ohashi and Erickson
suggested a model of sFn formation whereby anastellin binds and
partially unfolds F3 modules and prevents refolding, thus exposing
hydrophobic surfaces and b-sheet edges. The exposed elements
bind to similar exposed elements on other Fn modules, leading to a
specific aggregation [11]. sFn dramatically enhances cell adhesion
compared to plasma Fn when coated on a cell culture dish [9], and
it has been demonstrated that anastellin can inhibit angiogenesis.
This effect is believed to represent the basis for anastellin’s
observed anti-tumor activity in mouse models of human cancers
[12,13]. McKeown-Longo, et al. showed that anastellin added to
cultured cells becomes incorporated into the Fn matrix deposited
by the cells and induces a conformational rearrangement in the Fn
matrix that can be monitored by a specific monoclonal antibody.
Anastellin also effectively blocks serum-dependent proliferation of
cultured endothelial cells. This effect is not due to induced
apoptosis, but is caused by blocking the serum-dependent
activation of ERK [14].
More than 100 differentFn-bindingmicrobial proteinshave been
reported so far, although most of the Fn-microbial protein
interactions have not been characterized in detail. Previously, we
showed that the Fn-binding MSCRAMMs, FnBPA and FnBPB
from Staphylococcus aureus and Sfb1 from Streptococcus pyogenes, contain
a common motif that allows these proteins to bind to the N-terminal
domain (NTD) of Fn by a unique binding mechanism that we called
the tandem b-zipper. When these MSCRAMMs target soluble Fn,
the compact conformation of the host protein undergoes a change
resulting in a more open structure, where binding sites for the a5b1
integrin are exposed (Liang, et al., in preparation). Thus,
staphylococci or streptococci recruiting Fn to their surfaces via
these MSCRAMMs are coated with activated Fn that can lead to
a5b1 integrin-dependent host cell invasion.
Fn-binding MSCRAMMs can also bind to other domains in Fn.
A motif targeting the gelatin binding domain (GBD) in Fn has
been identified in Sfb1. ShdA of Salmonella enterica serotype
Typhimurium appears to target the F3 module,
13F3 (which
makes up part of the heparin-2-binding domain of Fn) [15]. The
binding motif in ShdA has not been clearly defined. Furthermore,
the biological consequences of these interactions are still unclear.
We have unsuccessfully searched many of the identified Fn-
binding MSCRAMMs for the presence of the motifs identified
from FnBPA, FnBPB, and Sfb1 that target the Fn NTD or GBD.
An exception is BBK32 from Borrelia burgdorferi. BBK32, a 47 kDa
lipoprotein, was originally identified as a Fn-binding MSCRAMM
by probing lysates of spirochete with Fn in Western ligand blots
[16]. It was localized to the surface of the spirochete and the
attachment of B. burgdorferi to Fn substrates was inhibited by the
addition of soluble recombinant BBK32 protein suggesting that
BBK32 is a Fn-binding adhesin on B. burgdorferi sensu stricto [16].
Orthologous genes are found in the closely related species, B.
garinii and B. afzelii [17]. Expression of BBK32 at the site of
experimental infection in mice increases until day 7 and then
declines, but bbk32 gene expression can be detected in the skin,
heart, spleen, joints, and bladder at least 30 days post challenge,
indicating that the lipoprotein is expressed by the spirochete as it
disseminates to different tissues in the host [18].
The N-terminus of BBK32 contains a signal peptide followed by
a ‘‘lipobox’’ and an extended intrinsically disordered segment
(residues 21–205) that contains the Fn-binding sites [19]. This
segment contains a sequence motif that resembles the motifs in
FnbpA. In fact, BBK32(147–205) binds to the N-terminal type I
modules found in Fn by the tandem b-zipper mechanism [20]. In
addition, we identified a motif resembling the GBD-binding
sequence in Sfb1 [20].
In further analysis of the binding specificity, we found that the
MSCRAMM not only binds to the NTD F1 modules [19,20] and
the GBD (manuscript in preparation), but also the
1–2F3, and
3F3
modules. This observation prompted us to examine if BBK32, like
anastellin can induce conformational changes in soluble Fn that can
lead to aggregation of the glycoprotein. Here we report that the
BBK32-F3 interaction induces an ordered aggregation of soluble Fn
that exposes thermolysincleavage sitesthatarecrypticinsolubleFn.
Recombinant BBK32 has specific biological activities in that it can
affect the structure of Fn matrices formed by cultured fibroblasts
and effectively inhibit endothelial cell proliferation. Furthermore,
we have identified two specific amino acid sequence motifs found in
BBK32 that can induce Fn aggregation. Thus, we conclude that a
specific motif in BBK32 can target F3 modules in Fn and induce the
formation of ordered Fn aggregates.
Results
BBK32 binds to
1–3F3 of Fn
We previously reported that the Fn-binding activity of BBK32 is
located to an intrinsically disordered segment of the protein
corresponding to residues 21–205 [19] and that a motif
corresponding to residues 147–205 binds to the
1F1–
5F1 N-
terminal segment of Fn by the tandem b-zipper mechanism
[19,20]. Experiments designed to further define the MSCRAMM
binding sites in Fn by probing a thermolysin digest of Fn with
rBBK32 (21–205) in Western ligand blots to determine the protein-
protein interaction, indicated that the MSCRAMM binds more
strongly to the 56 kDa fragment than to the 43 kDa gelatin
binding fragment (data not shown). Since the only difference
between these two Fn fragments is the inclusion of
1F3 in the
56 kDa fragment, this result suggests that BBK32 (21–205) may
interact with the
1F3 module. We, therefore, generated recombi-
nant forms of
1F3,
1–2F3, and
3F3 and examined the binding of
BBK32 to these Fn modules in ELISA-type binding assays.
BBK32 bound all the recombinant F3 modules in a concentration
dependent manner. The binding to the F3 module was specific for
BBK32 as the D3 fragment of S. aureus FnbpA, which binds
1F1–
5F1, did not to bind the F3 modules (Fig. 1). We calculated
half-maximal binding concentrations of 76.9 nM, 353 nM, and
188.1 nM for the binding of rBBK32 (21–205) to the
1F3,
1–2F3, and
3F3 respectively, indicating that the MSCRAMM has a high
affinity for the immobilized F3 modules.
BBK32 aggregates plasma Fn in a concentration
dependent manner
The interaction of BBK32 with
1F3,
1–2F3, and
3F3 is
particularly interesting since anastellin, an inducer of sFn, also
Bacteria Modify Fibronectin
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BBK32 could induce a form of Fn aggregation. To test this
possibility we incubated 1 mM of purified plasma Fn with increasing
concentrations of rBBK32 (21–205), anastellin, or the FnbpA D3
fragment.BBK32 and anastellin,butnotthe D3 protein inducedFn
aggregation that could be followed by the increase in absorbance at
600 nm (Fig. 2a). Fn aggregation was dependent on the concen-
tration of the inducer, and anastellin and rBBK32 (21–205) showed
very similar activity with measurableaggregationinitiatedat 20 mM
of the inducer. Aggregation of Fn was also observed with full length
BBK32, which includes the C-terminal globular domain (residues
21–354) (Fig. 2b). rBBK32 (21–354) was more active and induced
aggregation of Fn at lower concentrations than rBBK32 (21–205).
However, since the longer form of BBK32 is more susceptible to
degradation, we used rBBK32 (21–205) to further characterize the
BBK32-dependent Fn aggregation.
Initial experiments showed that addition of a detergent, Triton X-
100, inhibited Fn aggregation by BBK32 (not shown) as was
previously reported for anastellin induced Fn aggregation [11]. When
plasmaFnisinducedtoaggregatebyanastellintheproteinapparently
undergoes conformational changes. These changes involve exposure
of cryptic thermolysin cleavage sites which result in unique fragments
generated by enzymaticdigestion [11]. To determine if BBK32 elicits
a similar effect, we digested purified plasma Fn and Fn aggregates
induced by anastellin or rBBK32 (21–205) with thermolysin and
fractionated the resulting peptides by SDS-PAGE. As seen in
figure 3, digestion of Fn aggregates induced by anastellin or
BBK32 resulted in very similar fragment profiles. Furthermore,
some of the generated peptides are uniquely found in the
rBBK32(21–205)/Fn or anastellin/Fn digests and are not present
among the peptides obtained from digested purified plasma Fn.
The bands indicated by arrows in the SDS-PAGE (and
Figure 1. BBK32 (21–205) binds F3 modules. Binding to (a)
1F3 (b)
1–2F3 and (c)
3F3 was assessed using ELISA-type assays. F3 modules were
immobilized in microtiter wells followed by blocking with ovalbumin. BBK32 (21–205) or FnbpA peptide D3 was added to wells in increasing
concentrations. Anti-BBK32 antibody followed by HRP conjugated anti-rabbit antibody for BBK32 (21–205), and anti-FnbpA followed by HRP
conjugated anti-rabbit antibody were used to demonstrate binding.
doi:10.1371/journal.pone.0005412.g001
Figure 2. BBK32 (21–205) and BBK32 (21–354) aggregate plasma Fn.
(a) BBK32 (21–205), FnbpA peptide D3, and anastellin (b) or BBK32 (21–354)
and BBK32 (21–205) were titrated into 1 mM purified plasma Fn and
the optical density at 600 nm was measured.
doi:10.1371/journal.pone.0005412.g002
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to N-terminal sequencing. The sequences obtained, SSPVVID,
AVEENQE, and ITETIP, were located at the C-terminus of
13F3,
the middle of
3F3, and near the N-terminus of
1F3 respectively
(Fig. 3b). N-terminal sequencing of the material recovered from the
corresponding space from the plasma Fn only digest did not detect
these sequences. Taken together, these results suggest that
aggregation of plasma Fn by BBK32 or anastellin involves similar
types of conformational changes in the glycoprotein and that these
conformational changes are not limited to the
1–3F3 region but
extend towards the C-terminus of the protein.
BBK32 affects the structural organization of Fn matrix
assembly
The addition of Fn-binding MSCRAMMs or anastellin to
fibroblast cultures results in the incorporation of the exogenous
proteins into the extracellular matrix formed by the cultured cells.
Figure 3. BBK32 (21–205) induces a conformational change in plasma Fn. (a) Purified plasma Fn and Fn aggregates induced by anastellin or
BBK32 (21–205) weredigested withthermolysin. The digestedproductswerefractionatedbySDS-PAGEand peptides thatwereonlyfoundin BBK32 (21–205)
/Fn (lane 3) or anastellin/Fn (lane 2) digests and not present among the peptides obtained from purified plasma Fn (lane 1) were excised and
identified by N-terminal sequencing. The sequences obtained, SSPVVID, AVEENQE, and ITETIP, were located to the end of
13F3, middle of
3F3,
and the start of
1F3, respectively for both BBK32/Fn and anastellin/Fn. Pre-stained protein standards with indicated Mw are shown. (b)
Schematic of Fn. Stars denote cryptic cleavage sites in Fn after aggregation due to both BBK32 and anastellin.
doi:10.1371/journal.pone.0005412.g003
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the extracellular matrix of normal human dermal fibroblasts (data
not shown).
The interaction of anastellin and Fn results in conformational
changes in cellular Fn that can be monitored using a monoclonal
antibody specific to the alternatively spliced extra domain A (EDA).
EDA is only expressed in cellular Fn and is upregulated during
embryogenesis, wound healing, and tumor progression. Monoclo-
nal antibody IST 9, which targets residues
39PEDGIHELFP
48
found in the C-C’ loop of EDA [22,23], does not recognize cellular
Fn in the presence of anastellin [24]. Binding of anastellin to Fn
appears to induce a conformational change in EDA resulting in the
loss of the IST 9 epitope. As seen in figure 4, the addition of
anastellin (5 mM) to cultured NHDFs results in markedly reduced
immunostaining with IST9.Addition ofrBBK32(21–205) (5 mM)also
results ina reductionofimmunostaining with IST9 (Fig. 4).TheD3
fragment of FnbpA was used as a control. IST 9 staining of D3
treated cells was no different from the staining observed for the no
treatment control (Fig. 4). Polyclonal anti-Fn and monoclonal IST 1
(not shown), which recognizes an epitope in
12F3, were used to
demonstrate the presence of Fn in BBK32 or anastellin treated
matrices. The marked reduction in immunostaining with IST 9
indicates that BBK32 may alter the conformation of cellular Fn in a
manner similar to that seen with anastellin.
BBK32 inhibits the proliferation of cultured endothelial
cells
The ability of anastellin to inhibit endothelial cell proliferation
is one of its most prominent activities [13,14,25]. Since BBK32
behaves like anastellin in its interaction with Fn, we examined
the ability of BBK32 to affect proliferation of human umbilical
vein endothelial cells (Fig. 5). As before, we used anastellin and
the D3 fragment of FnbpA as controls. The results show that
BBK32 inhibited the proliferation of endothelial cells in a
concentration dependent manner as observed for anastellin.
Surprisingly, BBK32 was reproducibly more potent at inhibiting
endothelial cell proliferation than anastellin. The decrease in
proliferation was observed at 24 and 48 hours (data not shown),
but was more pronounced following 72 hours of static culture.
The FnbpA peptide D3 only marginally affected the proliferation
of cells.
The inhibition of endothelial cell proliferation was apparently
not due to apoptosis since Annexin V assays were negative (not
shown). Ambesi et al. demonstrated that anastellin inhibits
endothelial cell proliferation by causing G1 arrest [14]. Since
BBK32 does not induce apoptosis and there is no evidence of cell
death, it is tempting to speculate that the BBK32-dependent
inhibition of endothelial cell proliferation may also be due to cell
cycle arrest.
Figure 4. BBK32 (21–205) effects on Fn matrix assembled by NHDFs. Cells were incubated for 48 hours and then incubated with 5 mM
BBK32 (21–205),5mM anastellin, or 5 mM FnbpA peptide D3. Treated cells were incubated for 20 hours and probed with Alexa Fluor 488-anti-Fn and
monoclonal antibody IST 9. Images were taken using LSM 510 Confocal Microscope, objective 63X/1.4 oil. Bar=10 mm.
doi:10.1371/journal.pone.0005412.g004
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Since the Fn-binding region of BBK32 corresponding to
residues 21–205 has a disordered structure it is reasonable to
assume that a linear sequence is responsible for the sFn inducing
activity. To locate this hypothetical motif, we first examined the
activity of shorter recombinant fragments. Using ELISA-type
solid phase binding assays, we identified a F3-binding site to a
region between BBK32 residues 146 and 205 (data not shown).
We then synthesized and examined the activity of a panel of
peptides covering the segment between residues 146 and 202
(Table 1).
sBBK32(153–175) aggregated plasma Fn in a concentration-
dependent manner and was essentially as active as anastellin, whereas
the other two peptides (sBBK32(146–166) and sBBK32 (175–202))h a d
minimal activity (Fig. 6a). The addition of 5 mM BBK32 (153–175)
resulted in a reduction of immunostaining with IST 9. On the other
hand, BBK32 peptides 146–166, 153–166, and 175–202 did not
affect monoclonal antibody IST 9 recognition of EDA (Fig. 6b).
Addition of the BBK32 peptide 153–175 resulted in inhibition of
endothelial cell proliferation (Fig. 6c). In fact, this peptide was
consistently more active than anastellin or BBK32 (21–205). Peptide
175–202 had a minimal effect on HUVEC proliferation.
Taken together our data suggest that the sFn-inducing
activity in BBK32 is located to a site between residues 160–
175.
A conserved sequence motif in BBK32 and anastellin
induces ordered Fn aggregation
Alignment of the 160–175 segment of BBK32 and anastellin
revealed two distinct regions of weak sequence similarity (Fig. 7).
In order to further delineate the specific BBK32 motif capable of
aggregating Fn, we examined three additional synthetic peptides
(residues 160–175, 160–168, and 168–175) that correspond to the
intact or split motif conserved between anastellin and BBK32.
Synthetic BBK32 peptides 160–186, 160–175, 160–167, and 168–
175 all caused Fn to aggregate as measured by optical density at
600 nm. Peptide 160–175 was the most effective aggregation
inducer (Fig. 8), but both sBBK32 (160–167) and sBBK32 (168–175)
induced Fn aggregation in our assay. In addition, a scramble
peptide including the entire active motif (residues 160–186) is
unable to aggregate Fn. NMR data indicate that in anastellin, the
two active motifs are separated by 28 amino acids, but when the
protein is folded, the two sequences are in close proximity to each
other (Fig. 7). One of the active motifs in anastellin is found on a b-
strand that is not exposed in the
1F3 module (Fig. 7), whereas the
other motif is found in a short loop.
Figure 5. BBK32 (21–205) inhibits the proliferation of HUVECs. Cells were seeded onto tissue culture plates in full media and allowed to adhere
for two hours. After two hours, BBK32, anastellin, and FnbpA peptide D3 were added in increasing concentrations (in triplicate) to the wells. Cells
were then incubated for 72 hours at 37uC, 5% CO2. After 72 hours, cells were washed, trypsinized, and counted (three counts/well, three wells/dose)
using a hemacytometer.
doi:10.1371/journal.pone.0005412.g005
Table 1. Panel of synthetic BBK32 peptides used in experiments.
Construct Residues Aggregate Fn
Inhibit
Proliferation
rBBK32 (145–205) EEPIESNEIDLTIDSDLRPKSSLQGIAGSNSISYTDEIEEEDYDQYYLDEYDEEDEEEDYD Yes Yes
sBBK32 (146–166) EPIESNEIDLTIDSDLRPKSS No Yes
sBBK32 (153–175) IDLTIDSDLRPKSSLQGIAGSNS Yes Yes
sBBK32 (175–202) SISYTDEIEEEDYDQYYLDEYDEEDEEE No No
sBBK32 (160–186) DLRPKSSLQGIAGSNSISYTDEIEEED Yes Yes
sBBK32 (160–
186)scramble
GSELYESDISPENKIGQSDISRDTELA No No
sBBK32 (153–166) IDLTIDSDLRPKSS No No
sBBK32 (160–175) DLRPKSSLQGIAGSNS Yes Yes
sBBK32 (160–167) DLRPKSSL Yes Not Tested
sBBK32 (168–175) QGIAGSNS Yes Not Tested
doi:10.1371/journal.pone.0005412.t001
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PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5412Figure 6. BBK32 (153–175) aggregates plasma Fn. (a) BBK32 (21–205), BBK32 (146–166), BBK32 (153–175), and BBK32 (175–202) were titrated into 1 mM
purified plasma Fn and the optical density at 600 nm was measured. (b) BBK32 (153–175) is the minimal amino acid sequence required to affect Fn matrices
assembled by NHDFs. Cells were allowed to grow for 48 hours and then were incubated with 5 mM BBK32 (153–166),B B K 3 2(146–166), BBK32 (153–166), and
BBK32 (175–202). Treated cells were incubated for 20 hours and probed with Alexa Fluor 488-anti-Fn and monoclonal antibody IST 9. Images
were taken using LSM 510 Confocal Microscope, objective 63X/1.4 oil. Bar=10 mm. Staining with monoclonal antibody IST 9 indicates that
only the BBK32 peptide containing residues 153–175 changes the conformation of Fn matrices. (c) BBK32 (153–175) is the minimal amino acid
sequence required to inhibit HUVEC proliferation. Cells were seeded onto tissue culture plates in full media and allowed to adhere for two
hours. After two hours, BBK32 (21–205), BBK32 (153–175), BBK32 (175–202), and anastellin were added in increasing concentrations (in triplicate) to
the wells. Cells were then incubated for 72 hours at 37uC, 5% CO2. After 72 hours, cells were washed, trypsinized, and counted (three counts/
well, three wells/dose) using a hemacytometer.
doi:10.1371/journal.pone.0005412.g006
Figure 7. Amino acid sequence alignment of BBK32(153–175) and anastellin demonstrates weak homology. (A) NMR structure of
anastellin demonstrating homologous amino acids and (B) NMR structure of
1F3.
doi:10.1371/journal.pone.0005412.g007
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The B. burgdorferi lipoprotein BBK32 was previously shown to
bind to the N-terminal
1F1–
5F1 segment of Fn through a tandem
b-zipper mechanism [19,20]. We now demonstrate that a
recombinant form of BBK32 (21–205) also binds to Fn F3 modules
and can induce an ordered Fn aggregation that resembles the
formation of sFn induced by anastellin. This aggregation probably
is a consequence of conformational changes induced in Fn upon
BBK32 or anastellin binding. Aggregates of plasma Fn induced by
either BBK32 or anastellin expose similar thermolysin cleavage
sites. Both proteins affect the structure of cellular Fn in deposited
matrices by cultured fibroblasts as monitored by the disappearance
of the epitope for the monoclonal antibody IST9. Furthermore,
both BBK32 and anastellin can inhibit the proliferation of cultured
endothelial cells. Thus, BBK32 and anastellin appear to modulate
the conformation of Fn in similar ways and have similar biological
activities. The ability to induce ordered Fn aggregation is not a
property seen for all Fn-binding MSCRAMMs. A segment of the
staphylococcal Fn-binding MSCRAMM FnbpA did not show
these effects. The FnbpA D3 segment contains a well defined
4F1–
5F1 binding motif, but does not bind to F3 modules nor does
it induce Fn aggregation.
The Fn-binding activity of BBK32 was previously located to an
intrinsically disordered segment of the lipoprotein corresponding
to residues 21–205. The sequence 147–205, found within the
segment, binds the Fn NTD and resembles the NTD-binding
motifs identified in FnbpA of S. aureus and Sfb1 of S. pyogenes.
BBK32 also includes a putative gelatin binding domain (GBD)-
binding motif corresponding to residues 120–147 [20] that is
similar to a motif in Sfb1 that has GBD-binding activity
[26,27,28]. Now, we have identified a F3 binding motif in the
BBK32 Fn-binding segment. This F3-binding motif is located
within residues 147–205. It is interesting to note that the NTD-
binding motif in BBK32 also is located to residues 147–205.
Residues 165–182 contain the
2F1
3F1 binding motif and residues
146–162 contain the
4F1
5F1 binding motif [20]. Soluble Fn is
stabilized by intramolecular ionic interactions between specific
modules. These interactions occur among the
1F1–
5F1, the
2F3–
3F3, and the
12F3–
14F3 segments [3]. Binding to the NTD
might cause a conformational change in the F3 modules that could
then be stabilized by a BBK32-F3 module interaction leading to
Fn aggregation.
The F3-binding motif from BBK32 is also present in anastellin.
The residues in BBK32 that appear to comprise the sFn-inducing
motif have weak sequence homology to a sequence found in
anastellin (Fig. 8). Recombinant anastellin and BBK32 are
structurally different. Anastellin represents the C-terminal two-
thirds of the Fn
1F3 module, and has a defined structure with two
b-sheets. When both proteins are aligned the motif appears to be
divided, however, when anastellin is properly folded, the residues
are in close proximity and are available for Fn interactions (Fig. 8).
The active sFn-inducing motif in anastellin has not yet been
elucidated, however, residues QLISI (weak homology to the
QGIAG sequence in BBK32 (168–175)), are only exposed in
anastellin and not in the complete
1F3 module. The RPKNSV
sequence identified in anastellin is in a short loop region of the
protein where it could have a restricted flexibility in the intact F3
module. In anastellin, the
1F3 module is truncated. This
truncation might lead to a partial unfolding which might release
the structural constraints of the fold. BLAST [29] searches using
the intact or divided F3-binding motifs as probes reveal a number
of microbial and mammalian proteins containing related motifs
(data not shown). Some of the identified proteins are known to
bind Fn. These include the microbial proteins Efb from
Staphylococcus aureus [30] and Sfb1 Streptococcus pyogenes [31] and a
segment in human type I collagen which induces Fn fibrillogenesis
[32].
We have shown that full length BBK32 (residues 21–354) is
active and can induce sFn formation. It should be pointed out that
this is the first native protein shown to have sFn-inducing activity.
Anastellin is an artificial, recombinant fragment that is probably
not present in vivo. Although it is yet unknown whether intact
BBK32 expressed on the surface of B. burgdorferi induces sFn, we
can speculate about potential biological consequences of BBK32-
induced-sFn formation. The ability of BBK32 to inhibit
endothelial cell proliferation, which may be a function of sFn,
may ultimately facilitate the hematogenous spread of the
spirochetes that are initially locally deposited at the tick bite site.
During this process the spirochetes have to cross the endothelial
lining twice, once to enter the blood stream and once to exit.
Elegant studies by Norman, et al., demonstrated, using intravital
microscopy, that a non-infectious strain of B. burgdorferi lacking
BBK32, among other lipoproteins (VlsE, OspF, Erpl, and ErpK),
had fewer transient interactions, dragging interactions, and
stationary adhesions per minute with the endothelium in a live
murine infection model. When the non-infectious strain of B.
burgdorferi was complemented with BBK32, the numbers of
interactions per minute were restored to the same levels of the
infectious strain [33]. This indicates that BBK32 plays an
important role in B. burgdorferi-endothelium interactions. The
results of this study correlate well with earlier studies that
Figure 8. BBK32 (160–175) aggregates plasma Fn. BBK32 (160–175), BBK32 (160–167), BBK32 (168–175), BBK32 (160–186), and BBK32 (160–186)scramble were
titrated into 1 mM purified plasma Fn and the optical density at 600 nm was measured.
doi:10.1371/journal.pone.0005412.g008
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burgdorferi in vitro [34,35,36,37,38]. In addition, in a mouse model of
Lyme disease, B. burgdorferi mutant strains containing bbk32 gene
deletions have an attenuated infectivity when assessed at twenty-
one days post infection [39], demonstrating that BBK32 is a
virulence factor in borrelioses.
It is also intriguing that BBK32 induces a conformational
change in tissue Fn that can be monitored by the loss of the
epitope recognized by the monoclonal antibody IST 9. This
epitope has been located to the EDA module (specifically residues
39PEDGIHELFP
48) that also harbors binding sites for the a4b1
and a9b1 integrins [40]. Thus, it is possible that binding of BBK32
to Fn may regulate Fn’s interactions with these integrins, which in
turn may benefit the spirochetes. The effects of BBK32 on Fn
interactions with different integrins are currently being investigat-
ed in our laboratory.
Materials and Methods
Proteins
The anastellin construct was generously provided by Dr. Paula
McKeown-Longo (Albany Medical College). A recombinant protein
(amino acids: NAPQPSH….LISIQQ) with a C-terminal His-tag
was produced in bacteria and purified [9,24,25]. Recombinant
BBK32 (21–205) was expressed and purified as described [19].
Recombinant (r) F3 modules (amino acids:
1F3: SGPVE….DFTTT,
1–2F3: SGPVE …. TSQTT, and
3F3: APDAP …. QETTG) were
expressed with N-terminal His-tags and purified by standard Ni-
NTA and ion-exchange chromatography. FnbpA peptide D3
(HGFN….LPKV), synthetic (s) BBK32 (146–166),s B B K 3 2(153–166),
sBBK32 (153–175), sBBK32 (175–202), sBBK32 (160–186), and
sBBK32 (160–186)scramble were synthesized and purified by HPLC
using previously described methods [41]. sBBK32 peptides 160–
175, 160–167, and 168–175 were synthesized and purified to at
least 98% by BioMatik Corporation (Cambridge, ON, Canada).
Molecular weights were determined by mass spectrometry (Tufts
Core Facility, Boston, MA). Plasma Fn was affinity purified
from human plasma (Gulf Coast Regional Blood Center
Houston, TX) as described previously [42]. Protein concentra-
tions were calculated using absorbance at 280 nm.
ELISA-type binding assay
Binding of BBK32 to F3 modules was tested by coating 1 mgo f
recombinant
1F3,
1–2F3, and
3F3 modules in 50 ml of 50 mM Tris-
HCl, 150 mM NaCl, pH 7.5 (TBS) per well in Immulon 4HBX
microtiter plates (Dynatech Laboratories, Chantilly, VA) and
incubating overnight at 4uC. The next day, the wells were washed
with 200 ml TBS, 0.05% Tween 20, pH 7.4 (TBST) and blocked
with 200 ml TBST containing 2% ovalbumin (Sigma, St. Louis,
MO) for one hour at room temperature. The wells were then
washed and rBBK32 (21–205) or peptide D3 from FnbpA was added
to the wells in increasing concentrations. Plates were incubated for
one hour at room temperature. After washing with TBST,
primary antibodies (rabbit IgG anti-BBK32 or rabbit IgG anti-
FnbpA, produced by Rockland, Gilbertsville, PA) were added to
each well at a concentration of 0.48 mg/ml. Plates were incubated
for one hour at room temperature. Following washing with TBST,
a 1:3000 dilution of HRP-conjugated goat-anti-rabbit antibodies
(BioRad, Hercules, CA) was added to each well. Plates were
incubated for one hour at room temperature and then washed
with TBST. Color was developed by adding SigmaFast
TM
OPD
(Sigma) to each well and incubating at room temperature for
10 minutes. Absorbance was measured at 450 nm using a Thermo
Max microplate reader (Molecular Devices, Sunnyvale, CA). Half-
maximal binding was assessed using GraphPad Prism 4.
Fn aggregation assay
rBBK32 (21–354),rBBK32 (21–205),sBBK32 (146–166),sBBK32 (153–175),
sBBK32 (175–202), sBBK32 (160–167), sBBK32 (160–175),s B B K 3 2(168–175),
sBBK32 (160–186), sBBK32 (160–186)scramble, FnbpA peptide D3,
anastellin, and purified plasma Fn were centrifuged at
14,000 rpm for 15 minutes and then filtered through 0.22 mm
PES syringe filters (Nalgene, Rochester, NY). Following
filtration, BBK32, FnbpA peptide D3, and anastellin were
titrated into 1 mM purified plasma Fn in TBS. After the
addition of each aliquot, the Fn/protein mixture was carefully
mixed five times with a 200 ml pipette and optical density at
600 nm was measured using a BioPhotometer (Eppendorf, New
York, NY) after 10 seconds.
Proteolytic digestion of Fn aggregates
BBK32,anastellin,and plasmaFn weredialyzed into thermolysin
digestion buffer (25 mM Tris, 0.5 mM EDTA, pH 8, 50 mM
NaCl,and2.5 mMCaCl2).20 mMBBK32or20 mManastellinwas
added to 1 mM plasma Fn. Solutions were mixed and aggregates
were allowed to form for one hour at room temperature. After one
hour incubation, 5 mg/ml thermolysin (Sigma) was added to the
BBK32/Fn, the anastellin/Fn, and to plasma Fn. The solutions
were incubated at room temperature with end-over-end mixing for
2 hours. Digestion was stopped after two hours with the addition of
EDTA to a final concentration of 5 mM. Samples were then run on
4–20% gradient SDS-PAGE gels under non-reducing conditions.
ProteinfragmentsweretransferredtoPVDFmembranes(Millipore,
Billerica, MA)and stained with 0.25% Coomassie Brilliant blue-250
in 40% methanoluntil bands were visible. Excessstain was removed
with 40% methanol and bands that were present in BBK32/Fn and
anastellin/Fn, but not in plasma Fn lanes, were excised and
analyzed by N-terminal sequencing using Edman degradation
(Protein Sequencing Division, Tufts University Core Facility,
Boston, MA).
BBK32 effects on Fn matrix assembled by normal human
dermal fibroblasts
4610
4 adult normal human dermal fibroblasts (NHDFs)
(Cambrex, East Rutherford, NJ) were seeded onto glass coverslips
in 24 well Costar tissue culture plates in fibroblast growth media-2
(FGM-2) (Cambrex). Cells were incubated for 48 hours and then
rBBK32 (21–205), sBBK32 (146–166), sBBK32 (153–175), sBBK32 (175–202),
anastellin, or FnbpA peptide D3 was added to a final concentration
of 5 mM in FGM-2. Treated cells were incubated for 20 hours at
37uC, 5% CO2. After incubation, cells were washed with
Dulbecco’s PBS (DPBS) (Gibco, Invitrogen, Carlsbad, CA) and
fixed with 2% paraformaldehyde for 30 minutes at room
temperature. Following washing with DPBS, cells were blocked
with 1% BSA for one hour at room temperature. Cells were then
probed with Alexa Fluor 488-anti-Fn, and monoclonal antibodies
IST-9 (cellular Fn) (abcam, Cambridge, UK) or combinations of
antibodies at a dilution of 1:3000 for one hour at room temperature.
After incubation, cells were washed extensively with DPBS and
coverslips were mounted using Gel/Mount (biømeda, Foster City,
CA) onto glass slides and images were taken using a LSM 510
Confocal Microscope (Zeiss).
Endothelial cell proliferation assay
1610
4 human umbilical vein endothelial cells (HUVECs)
(Cambrex) were seeded into Costar 24 well tissue culture plates
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adhere for two hours. After two hours, rBBK32 (21–354), rBBK32
(21–205), sBBK32 (146–166), sBBK32 (153–175), sBBK32 (175–202),
anastellin, and FnbpA peptide D3 were added in a dose dependent
manner to the wells. Cells were incubated for 72 hours at 37uC,
5% CO2. After 72 hours, wells were washed with PBS and cells
were trypsinized with 0.5% trypsin/EDTA (Cambrex). Trypsin-
ized cells were collected in microcentrifuge tubes and trypsin/
EDTA was neutralized with EGM-2. Cells were counted from
each well (three counts/well, three wells/dose) using a hemacy-
tometer.
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